Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.62 USD | +0.65% | -16.35% | +5.37% |
30/05 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
23/05 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.37% | 2.42Cr | |
+46.01% | 5.79TCr | |
+40.74% | 4.03TCr | |
-6.91% | 3.99TCr | |
-5.16% | 2.85TCr | |
+11.02% | 2.64TCr | |
-20.77% | 1.93TCr | |
+29.66% | 1.24TCr | |
-1.45% | 1.22TCr | |
+23.32% | 1.22TCr |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Transcript : Viracta Therapeutics, Inc. - Special Call